PDGFRB and systemic sclerosis: A pathophysiological role may also be attributed to stimulatory autoantibodies against the platelet-derived growth factor receptor (PDGFR), which contributes to the pathogenesis of SSc by triggering the proliferation of fibroblasts and smooth muscle cells via two tyrosine-kinase receptors, PDGFRα and PDGFRβ [24].